No information is available on the clinical use of alectinib during breastfeeding. Because alectinib is more than 99% bound to plasma proteins, the amount in milk is low. However, its half-life is about 33 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during alectinib therapy and for 1 week after the last dose.
Drug Levels
Maternal Levels. A woman being treated with alectinib 600 mg once daily for lung cancer gave birth a normal infant. A milk sample taken postpartum contained 152 mcg/L of alectinib.[1] The time of the sample was not stated, but because of the drug’s long half-life, the timing might not be critical.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
1.
Shang M, Luo X, Wu J, et al. The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report. Lung Cancer. 2023;180:107188. [PubMed: 37087822]
Substance Identification
Substance Name
Alectinib
CAS Registry Number
1256580-46-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
Tyrosine Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
